Edwards Lifesciences Stock (EW) Falls as FTC Wins Ruling to Block JenaValve Deal
I'm PortAI, I can summarize articles.
Edwards Lifesciences (EW) faced a setback as the U.S. District Court ruled in favor of the FTC to block its acquisition of JenaValve Technology, causing EW stock to drop 1.32%. Following the ruling, Edwards announced it would not pursue the acquisition, despite believing it was in the best interest of patients. The company now expects 2026 adjusted EPS to be between $2.90 and $3.05. Wall Street maintains a Moderate Buy consensus on EW stock, with a price target suggesting a 13% upside potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments